No connection

Search Results

ABBV vs ANIP

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ANIP
ANI Pharmaceuticals, Inc.
BEARISH
Price
$70.49
Market Cap
$1.58B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ANIP
21.23
Forward P/E
ABBV
15.42
ANIP
6.82
P/B Ratio
ABBV
-146.66
ANIP
2.73
P/S Ratio
ABBV
6.5
ANIP
1.79
EV/EBITDA
ABBV
15.27
ANIP
10.33

Profitability

Gross Margin
ABBV
71.46%
ANIP
61.36%
Operating Margin
ABBV
35.5%
ANIP
11.99%
Profit Margin
ABBV
4.0%
ANIP
8.87%
ROE
ABBV
137.96%
ANIP
16.16%
ROA
ABBV
9.59%
ANIP
3.82%

Growth

Revenue Growth
ABBV
9.1%
ANIP
29.6%
Earnings Growth
ABBV
-88.7%
ANIP
--

Financial Health

Debt/Equity
ABBV
--
ANIP
1.16
Current Ratio
ABBV
0.72
ANIP
2.71
Quick Ratio
ABBV
0.47
ANIP
2.07

Dividends

Dividend Yield
ABBV
3.05%
ANIP
--
Payout Ratio
ABBV
490.15%
ANIP
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ANIP BEARISH

ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.

Strengths
Strong revenue growth of 29.6% YoY
High gross margin of 61.36%
Solid operating margin of 11.99%
Risks
Piotroski F-Score of 4/9 indicates weak financial health
No Altman Z-Score available, raising potential bankruptcy risk
Insider selling activity totaling $3.39M in last 6 months

Compare Another Pair

ABBV vs ANIP: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and ANI Pharmaceuticals, Inc. (ANIP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile